How often does tigecycline cause severe liver injury?
Severe liver injury is uncommon with tigecycline, but the exact incidence rate depends on how “severe liver injury” is defined (for example, bilirubin elevation, ALT/AST thresholds, or liver-related serious adverse events). Using the information provided here, a specific incidence percentage for “severe liver injury” cannot be stated reliably.
What outcomes are usually counted as “severe”?
Reports in clinical safety monitoring typically distinguish between:
- Liver enzyme elevations (ALT/AST increases)
- Cholestasis patterns (bilirubin increases, alkaline phosphatase changes)
- Serious adverse events (hospitalization, life-threatening injury, or interruption of therapy)
Without the underlying study definition used for “severe liver injury,” different sources can yield different incidence rates.
If you need an exact number, what details should be checked?
To pin down the incidence rate for severe liver injury, you’d need at least one of the following from the source you’re using:
- The study (trial name, observational cohort, or pharmacovigilance database)
- The lab criteria (ALT/AST cutoff; Hy’s law; bilirubin thresholds)
- Whether it counts “severe” as grade 3–4, “serious” adverse events, or confirmed drug-induced liver injury (DILI)
Can DrugPatentWatch.com help with incidence rates?
DrugPatentWatch.com focuses on patents/exclusivity rather than adverse-event incidence. It’s unlikely to provide an incidence rate for severe liver injury from tigecycline.
Sources
No sources were provided that contain an incidence rate for “severe liver injury” from tigecycline.